☆ 4.8 Editorial Material

Reproducibility in Cancer Biology: Small molecules remain on target for c-Myc

ELIFE (2017)

期刊

ELIFE

卷 6, 期 -, 页码 -

出版社

ELIFE SCIENCES PUBLICATIONS LTD

DOI: 10.7554/eLife.22915

关键词

-

类别

Biology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Chemistry, Medicinal

Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce c-MYC Protein Levels in Cells

Jesus R. Medina, Xinrong Tian, William H. Li, Dominic Suarez, James F. Mack, Louis LaFrance, Cuthbert Martyr, James Brackley, Christina Di Marco, Ralph Rivero, Dirk A. Heerding, Charles McHugh, Elisabeth Minthorn, Aishwarya Bhaskar, Jacob Rubin, Michael Butticello, Christopher Carpenter, Eldridge N. Nartey, Thomas J. Berrodin, Lorena A. Kallal, Biju Mangatt

Summary: The study identified an indirect strategy to target c-MYC and successfully discovered a series of compounds with c-MYC reducing effects. Through the medicinal chemistry program, the research team identified orally bioavailable potent c-MYC-reducing compounds. The study also developed a minimum pharmacophore model and a property-based approach to modulate pharmacokinetics properties.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Review Oncology

BIN1 in cancer: biomarker and therapeutic target

Si-yu Chen, Jin-long Cao, Kun-peng Li, Shun Wan, Li Yang

Summary: BIN1 protein has various physiological functions and is closely associated with the development of many diseases. Recent findings have revealed the potential mechanisms of BIN1 in cancer development and its feasibility as a prognostic marker and therapeutic target.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Target c-Myc to treat pancreatic cancer

Moein Ala

Summary: C-Myc overexpression in pancreatic cancer is associated with aggressive behavior of cancer cells and can regulate various cellular processes. Recent studies have shown that C-Myc can be targeted directly or indirectly, offering potential therapeutic strategies for pancreatic cancer.

CANCER BIOLOGY & THERAPY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

G-Quadruplexes in c-MYC Promoter as Targets for Cancer Therapy

Barbara Bahls, Israa M. Aljnadi, Rita Emidio, Eduarda Mendes, Alexandra Paulo

Summary: Cancer is a societal burden that requires innovative approaches due to the toxic side effects and poor selectivity of conventional chemotherapeutic agents. Uncontrolled proliferation of cancer cells is caused by mutations, deletions, or amplifications in genes encoding for proteins that regulate cell growth and division, such as c-MYC. Directly targeting the c-MYC protein has been unsuccessful, but the exploration of G-quadruplex structures in the c-MYC promoter region has shown promise in downregulating the transcription of this oncogene. In this article, we will overview the significant advancements made in the discovery of a new class of anticancer drugs that target G-quadruplexes in the c-MYC promoter of cancer cells.

BIOMEDICINES (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer

Yuxi Zhang, Yi Wang, Yanping Li, Cong Huang, Xiaoqian Xiao, Zhanqiong Zhong, Jingyi Tang, Haolan Lu, Yibei Tang, Jiahui Yang

Summary: In this study, it is shown that dihydroartemisinin (DHA) and artemisinin (AS) inhibit aerobic glycolysis in non-small cell lung cancer (NSCLC) cells through the ERK/c-Myc pathway, leading to the inhibition of tumor growth. This study expands our knowledge of artemisinin derivatives in regulating tumor glucose metabolism and provides a potential strategy for lung cancer therapy.

BIOCHEMICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Electrophilic reactive aldehydes as a therapeutic target in colorectal cancer prevention and treatment

Alain P. Gobert, Mohammad Asim, Thaddeus M. Smith, Kamery J. Williams, Daniel P. Barry, Margaret M. Allaman, Kara M. McNamara, Caroline V. Hawkins, Alberto G. Delgado, Shilin Zhao, M. Blanca Piazuelo, M. Kay Washington, Lori A. Coburn, John A. Rathmacher, Keith T. Wilson

Summary: This study found that isolevuglandins (isoLGs), formed from lipid peroxidation, covalently bind with amine-containing macromolecules in colonic epithelial cells of colorectal cancer (CRC) patients. The natural compound 2-hydroxybenzylamine (2-HOBA), a scavenger of electrophiles, was shown to reduce isoLG adduct levels, tumorigenesis, and oncogenic NRF2 activation in CRC models. In addition, 2-HOBA attenuated the growth of human CRC cells in animal models.

ONCOGENE (2023)

添加到收藏夹

Article Chemistry, Medicinal

Ribosomal proteinL5mediated inhibition ofc-Mycis critically involved in sanggenon G induced apoptosis in non-small lung cancer cells

Ji Eon Park, Ji Hoon Jung, Hyo-Jung Lee, Deok Yong Sim, Eunji Im, Woon Yi Park, Bum Sang Shim, Seong-Gyu Ko, Sung-Hoon Kim

Summary: The study revealed that Sanggenon G (SanG) can inhibit the viability of non-small lung cancer cells through multiple pathways, including inhibition of cyclins and apoptosis-related proteins. Additionally, SanG can induce apoptosis by activating caspase-3 and RPL5, showing potential for combination with other drugs.

PHYTOTHERAPY RESEARCH (2021)

添加到收藏夹

Article Cell Biology

MICAL-L2 Is Essential for c-Myc Deubiquitination and Stability in Non-small Cell Lung Cancer Cells

Pengxiang Min, Lin Zhang, Yueyuan Wang, Chenxiang Qi, Yixuan Song, Maria Bibi, Yujie Zhang, Yadong Ma, Xuyang Zhao, Minjie Yu, Jun Du

Summary: The study showed that MICAL-L2 is highly expressed in human NSCLC and plays a role in promoting cancer cell proliferation by interacting with and stabilizing c-Myc protein. Depletion of MICAL-L2 led to reduced c-Myc stability and decreased cancer cell proliferation. This suggests that MICAL-L2 may be a potential therapeutic target for NSCLC.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Alternative approaches to target Myc for cancer treatment

Chen Wang, Jiawei Zhang, Jie Yin, Yichao Gan, Senlin Xu, Ying Gu, Wendong Huang

Summary: The Myc proto-oncogene family consists of C-MYC, MYCN, and MYCL, encoding c-Myc, N-Myc, and L-Myc respectively. Myc protein orchestrates various physiological processes but its deregulation rewires signaling modules inside tumor cells. While more than 70% of human cancers show deregulation of Myc, there is currently no specific drug available to directly target it.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Pathology

Identification of a novel therapeutic target for lung cancer: Mitochondrial ribosome protein L9

Xin-Yuan Li, Xin-Yu He, Hong Zhao, Lu Qi, Jin-Jian Lu

Summary: This study identified MRPL9 as an upregulated gene in lung cancer tissues, which was associated with poor prognosis. Knockdown of MRPL9 inhibited lung cancer cell proliferation, sphere formation, and migration ability. MRPL9 was associated with the c-MYC signaling pathway and its co-expression with MYC correlated with a worse prognosis in lung cancer patients. Bioinformatics analysis revealed the association between c-MYC and the EMT regulator ZEB1. Interfering with c-MYC expression confirmed the relationship between ZEB1 and c-MYC. Thus, MRPL9 may serve as a potential therapeutic target for lung cancer by affecting c-MYC and regulating ZEB1.

PATHOLOGY RESEARCH AND PRACTICE (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Sex-biased genome-editing effects of CRISPR-Cas9 across cancer cells dependent on p53 status

Mengbiao Guo, Yuanyan Xiong

Summary: The CRISPR-Cas9 system is widely used for gene editing and clinical applications. However, it can cause off-target effects. This study found significant sex differences in p53-associated Cas9 activities. Further analysis revealed sex-specific dependencies of gene knockouts in different cancer types, potentially mediated by transcriptional factors. These findings suggest the need to consider the p53-dependent sex bias in future CRISPR-Cas9 clinical applications, especially in cancer.

ISCIENCE (2023)

添加到收藏夹

Review Oncology

Significant position of C-myc in colorectal cancer: a promising therapeutic target

Li Tan, Dong Peng, Yong Cheng

Summary: Colorectal cancer is a common malignant tumor globally, with increasing incidence and mortality in China. Despite the development of various treatment methods, overall survival for patients remains low. Past research has highlighted the significant role of c-myc in colorectal cancer, yet there are limited drugs targeting c-myc directly. Therefore, studying the mechanism of c-myc in colorectal cancer is of great importance in providing better treatment options for patients.

CLINICAL & TRANSLATIONAL ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

5-Hydroxytryptamine activates a 5-HT/c-Myc/SLC6A4 signaling loop in non-small cell lung cancer

Yuan Tu, Shengping Yao, Qiong Chen, Wenqin Li, Yinghui Song, Pei Zhang

Summary: 5-HT signaling plays a crucial role in the development of non-small cell lung cancer (NSCLC), and inhibitors of 5-HT uptake have potential therapeutic value in the treatment of NSCLC patients.

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

MYC promotes cancer progression by modulating m6A modifications to suppress target gene translation

Gongwei Wu, Caixia Suo, Ying Yang, Shengqi Shen, Linchong Sun, Shi-Ting Li, Yingli Zhou, Dongdong Yang, Yan Wang, Yongping Cai, Nana Wang, Huafeng Zhang, Yun-Gui Yang, Jie Cao, Ping Gao

Summary: The oncogene MYC promotes cancer progression by down-regulating N6-methyladenosine (m(6)A) modification preferentially in transcripts of MYC-repressed genes (MRGs). This alteration leads to the activation of ALKBH5 expression and reduction of m(6)A levels in specific MRGs, controlling their translation through the m(6)A reader YTHDF3. Ultimately, inhibiting ALKBH5 or overexpressing SPI1 or PHF12 effectively suppresses the growth of MYC-deregulated B-cell lymphomas.

EMBO REPORTS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

Jessica K. Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Wu, Bruna Almeida, Nathalie Legrave, Duco S. Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorian Sopena, James MacRae, Emma Nye, Michael Howell, Ambrosius P. Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, Axel Behrens

Summary: This study reveals that the deubiquitinating enzyme USP25 promotes growth and survival of pancreatic ductal adenocarcinoma (PDAC) by stabilizing and regulating the transcriptional activity of HIF-1 protein. PDAC is characterized by a severely hypoxic microenvironment, and inhibition of USP25 impairs HIF-1 activity and induces cell death in the tumor core. The USP25/HIF-1α axis may be a potential therapeutic target for PDAC.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect

Linchong Sun, Caixia Suo, Shi-ting Li, Huafeng Zhang, Ping Gao

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)

添加到收藏夹

Correction Multidisciplinary Sciences

Menin enhances c-Myc-mediated transcription to promote cancer progression (vol 8, 15278, 2017)

Gongwei Wu, Mengqiu Yuan, Shengqi Shen, Xiaoyu Ma, Jingwen Fang, Lianbang Zhu, Linchong Sun, Zhaoji Liu, Xiaoping He, De Huang, Tingting Li, Chenchen Li, Jun Wu, Xin Hu, Zhaoyong Li, Libing Song, Kun Qu, Huafeng Zhang, Ping Gao

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Cell Biology

2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1

Jiadong Cheng, Lan Hu, Zheng Yang, Caixia Suo, Yueyang Jack Wang, Ping Gao, Chengbin Cui, Linchong Sun

CELLS (2019)

添加到收藏夹

Article Oncology

DIS3L2 Promotes Progression of Hepatocellular Carcinoma via hnRNP U-Mediated Alternative Splicing

Songge Xing, Zhaoyong Li, Wenhao Ma, Xiaoping He, Shengqi Shen, Haoran Wei, Shi-Ting Li, Ying Shu, Linchong Sun, Xiuying Zhong, Yuhao Huangfu, Lanhong Su, Junru Feng, Xiaozhang Zhang, Ping Gao, Wei-Dong Jia, Huafeng Zhang

CANCER RESEARCH (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1

Yang Zhang, Chenchen Li, Chuanzhen Hu, Qian Wu, Yongping Cai, Songge Xing, Hui Lu, Lin Wang, De Huang, Linchong Sun, Tingting Li, Xiaoping He, Xiuying Zhong, Junfeng Wang, Ping Gao, Zachary J. Smith, Weidong Jia, Huafeng Zhang

EMBO REPORTS (2019)

添加到收藏夹

Article Oncology

Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1

Zhaoji Liu, Linchong Sun, Yongping Cai, Shengqi Shen, Tong Zhang, Nana Wang, Gongwei Wu, Wenhao Ma, Shi-Ting Li, Caixia Suo, Yijie Hao, Wei-Dong Jia, Gregg L. Semenza, Ping Gao, Huafeng Zhang

Summary: This study reveals that under hypoxic conditions, the alternative splicing of MBD2 is suppressed, leading to the production of MBD2a which promotes breast cancer metastasis. Clinical data show a significant correlation between the expression of MBD2a and MBD2c with the invasiveness of breast cancer, indicating their opposing roles in regulating metastasis in this disease.

CANCER RESEARCH (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

MYC promotes cancer progression by modulating m6A modifications to suppress target gene translation

Gongwei Wu, Caixia Suo, Ying Yang, Shengqi Shen, Linchong Sun, Shi-Ting Li, Yingli Zhou, Dongdong Yang, Yan Wang, Yongping Cai, Nana Wang, Huafeng Zhang, Yun-Gui Yang, Jie Cao, Ping Gao

Summary: The oncogene MYC promotes cancer progression by down-regulating N6-methyladenosine (m(6)A) modification preferentially in transcripts of MYC-repressed genes (MRGs). This alteration leads to the activation of ALKBH5 expression and reduction of m(6)A levels in specific MRGs, controlling their translation through the m(6)A reader YTHDF3. Ultimately, inhibiting ALKBH5 or overexpressing SPI1 or PHF12 effectively suppresses the growth of MYC-deregulated B-cell lymphomas.

EMBO REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CARS senses cysteine deprivation to activate AMPK for cell survival

Mengqiu Yuan, Ronghui Yan, Yi Zhang, Yue Qiu, Zetan Jiang, Haiying Liu, Ying Wang, Linchong Sun, Huafeng Zhang, Ping Gao

Summary: This study reveals that cysteine deficiency activates AMPK through CaMKK2, leading to cell death. Cysteine modulates AMPK activation by affecting the binding of CARS to AMPK.

EMBO JOURNAL (2021)

添加到收藏夹

Review Cell Biology

Metabolic reprogramming and epigenetic modifications on the path to cancer

Linchong Sun, Huafeng Zhang, Ping Gao

Summary: Metabolic rewiring and epigenetic remodeling, which are closely linked in cancer development, play important roles in tumor progression and immune escape. Metabolites can affect the function of chromatin-modifying enzymes, influencing processes such as tumor progression and immunosurveillance.

PROTEIN & CELL (2022)

添加到收藏夹

Article Oncology

KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression

Haoran Wei, Wenhao Ma, Xiaofei Lu, Haiying Liu, Kashuai Lin, Yinghui Wang, Zijian Ye, Linchong Sun, Zhitong Huang, Tingting Pan, Zilong Zhou, Eric Y. Cheng, Huafeng Zhang, Ping Gao, Xiuying Zhong

Summary: This study identified KDELR2 as a novel target of HDAC3, with aberrant expression indicating poor prognosis in breast cancer patients. The correlation between HDAC3 and KDELR2 in tumor tissues was confirmed. It was found that HDAC3 transactivated KDELR2 via CREB1, promoting cell cycle progression and tumorigenesis. The HDAC3-KDELR2 axis could be a potential therapeutic target for breast cancer.

CANCER COMMUNICATIONS (2021)

添加到收藏夹

Article Cell Biology

Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Yinghui Wang, Hui Lu, Linchong Sun, Xin Chen, Haoran Wei, Caixia Suo, Junru Feng, Mengqiu Yuan, Shengqi Shen, Weidong Jia, Ying Wang, Huafeng Zhang, Zijun Li, Xiuying Zhong, Ping Gao

Summary: Metformin increases sensitivity of hepatocarcinoma cells to methotrexate by suppressing DHFR expression, blocking nucleotide metabolism, and inhibiting cell cycle progression and tumorigenesis. It represses DHFR transcriptionally via E2F4 and promotes lysosomal degradation of DHFR protein. Metformin enhances patient-derived hepatocarcinoma organoids response to MTX without toxicity to normal liver organoids, suggesting a potential therapeutically targetable vulnerability in hepatocarcinoma.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Non-canonical phosphoglycerate dehydrogenase activity promotes liver cancer growth via mitochondrial translation and respiratory metabolism

Ying Shu, Yijie Hao, Junru Feng, Haiying Liu, Shi-ting Li, Jiaqian Feng, Zetan Jiang, Ling Ye, Yingli Zhou, Yuchen Sun, Zilong Zhou, Haoran Wei, Ping Gao, Huafeng Zhang, Linchong Sun

Summary: Phosphoglycerate dehydrogenase (PHGDH) plays a crucial role in tumorigenesis by promoting mitochondrial translation and bioenergetics.

EMBO JOURNAL (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism

Linchong Sun, Caixia Suo, Tong Zhang, Shengqi Shen, Xuemei Gu, Shiqiao Qiu, Pinggen Zhang, Haoran Wei, Wenhao Ma, Ronghui Yan, Rui Chen, Weidong Jia, Jie Cao, Huafeng Zhang, Ping Gao

Summary: Enolase 1 (ENO1) is a glycolytic enzyme that promotes cancer development through binding to YAP1 mRNA to enhance its translation, thereby activating alternative arachidonic acid metabolism and prostaglandin E-2 accumulation. Aberrant activation of ENO1/YAP1/PLCB1 and decreased HPGD expression in liver cancer samples suggest a potential correlation between ENO1-regulated AA metabolism and cancer development, highlighting the therapeutic potential of aspirin.

NATURE CHEMICAL BIOLOGY (2023)

添加到收藏夹

Article Oncology

ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1

Tong Zhang, Linchong Sun, Yijie Hao, Caixia Suo, Shengqi Shen, Haoran Wei, Wenhao Ma, Pinggen Zhang, Ting Wang, Xuemei Gu, Shi-Ting Li, Zhaolin Chen, Ronghui Yan, Yi Zhang, Yongping Cai, Rongbin Zhou, Weidong Jia, Fang Huang, Ping Gao, Huafeng Zhang

Summary: This study demonstrates the role of the glycolytic enzyme alpha-Enolase 1 in iron homeostasis and suppression of ferroptosis in hepatocellular carcinoma. The researchers found that ENO1 suppresses IRP1 expression to regulate iron balance in HCC cells, suggesting a potential innovative cancer therapy targeting the ENO1-IRP1-Mfrn1 pathway.

NATURE CANCER (2022)

添加到收藏夹

Review Physiology

Metabolic reprogramming and tumor immunity under hypoxic microenvironment

Ronghui Yan, Linchong Sun, Huafeng Zhang

CURRENT OPINION IN PHYSIOLOGY (2019)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.